Literature DB >> 22127921

The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease.

Pierre O'Brien1, Pier Morin, Rodney J Ouellette, Gilles A Robichaud.   

Abstract

The Pax-5 oncogene encodes a potent transcription factor that plays a key role in B-cell development and cancerous processes. In normal B-lymphopoiesis, Pax-5 accomplishes a dual function by activating B-cell commitment genes while concomitantly repressing non-B-lineage genes. Given the pivotal importance of Pax-5-mediated processes in B-cell development, an aberrant regulation of Pax5 expression has consistently been associated with B-cell cancers, namely, lymphoma and lymphocytic leukemias. More recently, Pax-5 gene expression has been proposed to influence carcinogenic events in tissues of nonlymphoid origin by promoting cell growth and survival. However, in other cases, Pax-5 products have opposing effects on proliferative activity, thus redefining its generally accepted role as an oncogene in cancer. In this review, we attempt to summarize recent findings about the function and regulation of Pax-5 gene products in B-cell development and related cancers. In addition, we present new findings that highlight the pleiotropic effects of Pax-5 activity in a number of other cancer types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127921     DOI: 10.1158/0008-5472.CAN-11-1874

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

Review 2.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Controlled expression of Drosophila homeobox loci using the Hostile takeover system.

Authors:  Naureen Javeed; Nicholas J Tardi; Maggie Maher; Swetha Singari; Kevin A Edwards
Journal:  Dev Dyn       Date:  2015-06       Impact factor: 3.780

Review 4.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

5.  MicroRNA 648 Targets ET-1 mRNA and is cotranscriptionally regulated with MICAL3 by PAX5.

Authors:  Chen Li; Caryn S Gonsalves; Marthe-Sandrine Eiymo Mwa Mpollo; Punam Malik; Stanley M Tahara; Vijay K Kalra
Journal:  Mol Cell Biol       Date:  2014-11-17       Impact factor: 4.272

6.  An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Authors:  Logan A Walsh; Mariano J Alvarez; Erich Y Sabio; Marsha Reyngold; Vladimir Makarov; Suranjit Mukherjee; Ken-Wing Lee; Alexis Desrichard; Şevin Turcan; Martin G Dalin; Vinagolu K Rajasekhar; Shuibing Chen; Linda T Vahdat; Andrea Califano; Timothy A Chan
Journal:  Cell Rep       Date:  2017-08-15       Impact factor: 9.423

7.  Analysis of chromatin-state plasticity identifies cell-type-specific regulators of H3K27me3 patterns.

Authors:  Luca Pinello; Jian Xu; Stuart H Orkin; Guo-Cheng Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

Review 8.  Chronic lymphocytic leukaemia.

Authors:  Thomas J Kipps; Freda K Stevenson; Catherine J Wu; Carlo M Croce; Graham Packham; William G Wierda; Susan O'Brien; John Gribben; Kanti Rai
Journal:  Nat Rev Dis Primers       Date:  2017-01-19       Impact factor: 52.329

9.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

10.  Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.

Authors:  Ana Livun; Kate J Newberry; Taghi Manshouri; Rajko Kusec; Srdan Verstovsek
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.